{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=43",
    "query": {
      "intervention": "Injectable Placebo",
      "page": 43
    },
    "page_size": 10
  },
  "pagination": {
    "page": 43,
    "page_size": 10,
    "total_count": 4208,
    "total_pages": 421,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=44&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=42&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T19:27:41.855Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00060892",
      "title": "Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arterial Occlusive Disease",
        "Peripheral Vascular Disease",
        "Ischemia"
      ],
      "interventions": [
        {
          "name": "HGF plasmid",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "AnGes USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2003-04",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2008-01-11",
      "last_synced_at": "2026-10-20T19:27:41.855Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00060892"
    },
    {
      "nct_id": "NCT00264537",
      "title": "A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Placebo injections",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsules",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate capsules",
          "type": "DRUG"
        },
        {
          "name": "Golimumab 50 mg injections",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Golimumab 100 mg injections",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Centocor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 637,
      "start_date": "2005-12",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2014-09-05",
      "last_synced_at": "2026-10-20T19:27:41.855Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Upland, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00264537"
    },
    {
      "nct_id": "NCT04625972",
      "title": "Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "AZD7442",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 1131,
      "start_date": "2020-12-02",
      "completion_date": "2022-07-25",
      "has_results": true,
      "last_update_posted_date": "2023-11-21",
      "last_synced_at": "2026-10-20T19:27:41.855Z",
      "location_count": 50,
      "location_summary": "Guntersville, Alabama • Tempe, Arizona • Little Rock, Arkansas + 42 more",
      "locations": [
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Corona",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04625972"
    },
    {
      "nct_id": "NCT02097277",
      "title": "A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [
        {
          "name": "BMS-986036",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Matching with BMS-986036)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 219,
      "start_date": "2014-04-15",
      "completion_date": "2016-05-17",
      "has_results": true,
      "last_update_posted_date": "2019-07-31",
      "last_synced_at": "2026-10-20T19:27:41.855Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Anaheim, California • Los Angeles, California + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02097277"
    },
    {
      "nct_id": "NCT03887377",
      "title": "The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Scar",
        "Hypertrophic Scar",
        "Mammary Disorder"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxins",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2019-06-10",
      "completion_date": "2024-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-15",
      "last_synced_at": "2026-10-20T19:27:41.855Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03887377"
    },
    {
      "nct_id": "NCT06947928",
      "title": "Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Advanced Or Metastatic Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "IFx-Hu2.0",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TuHURA Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2025-12-11",
      "completion_date": "2032-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-20T19:27:41.855Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06947928"
    },
    {
      "nct_id": "NCT05468736",
      "title": "Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Months to 11 Years"
      },
      "enrollment_count": 3600,
      "start_date": "2022-07-22",
      "completion_date": "2025-10-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-20T19:27:41.855Z",
      "location_count": 47,
      "location_summary": "Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Fair Oaks",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05468736"
    },
    {
      "nct_id": "NCT01919164",
      "title": "A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "Sprifermin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 549,
      "start_date": "2013-07-29",
      "completion_date": "2019-05-07",
      "has_results": true,
      "last_update_posted_date": "2020-07-13",
      "last_synced_at": "2026-10-20T19:27:41.855Z",
      "location_count": 2,
      "location_summary": "Lakewood, Colorado • Baltimore, Maryland",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01919164"
    },
    {
      "nct_id": "NCT00004984",
      "title": "The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Parenteral Insulin",
          "type": "DRUG"
        },
        {
          "name": "Close Observation",
          "type": "OTHER"
        },
        {
          "name": "Oral Insulin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "3 Years to 45 Years"
      },
      "enrollment_count": 711,
      "start_date": "1994-02",
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2020-04-24",
      "last_synced_at": "2026-10-20T19:27:41.855Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004984"
    },
    {
      "nct_id": "NCT01280149",
      "title": "Reduction of IgE Antibody in Human Allergic Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Seasonal Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "substance P",
          "type": "BIOLOGICAL"
        },
        {
          "name": "substance P injections",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2011-01",
      "completion_date": "2017-06-20",
      "has_results": false,
      "last_update_posted_date": "2018-08-21",
      "last_synced_at": "2026-10-20T19:27:41.855Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01280149"
    }
  ]
}